Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Emerg Med Clin North Am. 2016 Sep 3;34(4):883–899. doi: 10.1016/j.emc.2016.06.010

Table 2.

Effect of DOACs on blood tests Data from refs79,80,81

DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN
aPTT

  • Abnormal only at moderate/high levels of drug.

  • Provides only qualitative indication

  • Low sensitivity

  • ossible paradoxical response

  • Low sensitivity

  • Possible paradoxical response

  • Low sensitivity
PT/INR

  • High inter-individual variability

  • Mild effect (INR ranging from 0.9 to 1.2)

  • Provides qualitative indication only with specific reagents

  • Unaffected

  • Linear dose-dependent association but low sensitivity at lower therapeutic drug levels
Diluted Thrombin time (dTT)

  • Already prolonged at low drug concentration.

  • Normal dTT can rule out anticoagulant activity

  • Needs calibration
Ecarin clotting time (ECT)

  • Sensitive indicator

  • Not widely available

  • Time consuming
Anti Xa activity

  • Sensitive indicator

  • Normal value rules out anticoagulant activity.

  • Not widely available

  • Needs calibration

  • Sensitive indicator

  • Normal value rules out anticoagulant activity.

  • Not widely available

  • Needs calibration

  • Sensitive indicator

  • Normal value rules out anticoagulant activity.

  • Not widely available

  • Needs calibration
Specific test system Hemoclot ®: dabigatran calibrated dTT Rivaroxaban calibrated anti Xa activity Apixaban calibrated anti Xa activity Edoxaban calibrated anti Xa activity